Physician profile
Dilpat Kumar
NPI 1891355731
$1,384.82
in general payments reported to CMS, 2019-2025
11 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $136 · 2022: $264 · 2023: $317 · 2024: $423 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $739.35 | 2021-2025 | Lifevest |
| Pfizer INC. | $147.50 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $123.97 | 2021 | |
| Lantheus Medical Imaging, INC. | $80.91 | 2023 | Definity |
| Abbott Laboratories | $76.74 | 2023-2025 | Accent, Jot Dx, Quadra Assura |
| Abbvie INC. | $59.37 | 2024 | |
| Daiichi Sankyo INC. | $42.42 | 2023-2024 | Injectafer |
| Medtronic, INC. | $37.07 | 2022 | |
| Vital Connect, INC | $33.39 | 2024 | Vitalpatch Rtm |
| Actelion Pharmaceuticals US, INC. | $26.92 | 2024 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $17.18 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dilpat Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.